Related Experiment Videos
Phenotype and function of human dendritic cells derived from M-DC8(+) monocytes
A de Baey1, I Mende, G Riethmueller
1Micromet AG, Martinsried, Germany. annegret.debaey@micromet.de
European Journal of Immunology
|June 1, 2001
Summary
Monocytes identified by M-DC8 antibodies generate potent dendritic cells (DC) for cancer immunotherapy. These M-DC8(+) dendritic cells enhance T-cell responses more effectively than M-DC8(-) dendritic cells.
Area of Science:
- Immunology
- Cell Biology
- Cancer Research
Background:
- Dendritic cells (DC) derived from peripheral blood monocytes show promise in cancer immunotherapy.
- The specific monocyte subpopulations contributing to functional DC generation remain unclear.
- The M-DC8 monoclonal antibody identifies a rare subset of blood leukocytes.
Purpose of the Study:
- To identify and characterize the M-DC8(+) monocyte subpopulation.
- To evaluate the potential of M-DC8(+) monocytes for generating potent dendritic cells for immunotherapy.
Main Methods:
- Identification of M-DC8(+) cells within monocyte populations.
- Differentiation of M-DC8(+) and M-DC8(-) monocytes into dendritic cells using GM-CSF and IL-4.
- Analysis of DC phenotype, function, HLA molecule expression, IL-12p75 production, and T-cell priming capacity.
Main Results:
- M-DC8(+) cells were identified as a subset of CD14(low)CD16(+) monocytes.
- M-DC8(+) monocytes differentiated into homogeneous DC with comparable phenotype and function to M-DC8(-) derived DC.
- M-DC8(+) DC exhibited higher expression of HLA class I and II molecules and produced more IL-12p75.
- M-DC8(+) DC induced stronger Th1 immune responses and were 2-4 times more potent in priming cord blood T cells.
Conclusions:
- M-DC8(+) monocytes represent a valuable source for generating highly potent dendritic cells.
- These potent dendritic cells have the potential to significantly enhance the efficacy of dendritic cell-based cancer immunotherapies.